Please assess the completion status of the following clinical trial:

Trial Title: IVIG Treatment for Refractory Immune-Related Adult Epilepsy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of uncontrolled epilepsy with at least two seizures a month for three consecutive months.~* Age 18 to 50.~* Clinical semiology or electroencephalogram (EEG) consistent with partial onset epilepsy.~* Refractory to an adequate trial of two or more main-line anti-epileptic drugs.~* Ability to keep a seizure diary.~* Normal brain magnetic resonance imaging (MRI) - 3 Tesla, seizure protocol; with the exception of hippocampal sclerosis~Exclusion Criteria:~* History of severe prematurity or neonatal distress, febrile seizures, moderate or sever traumatic brain injury, stroke, brain tumor, meningitis, encephalitis, neurocutaneous syndromes, or intracranial metal objects.~* Evidence of psychogenic epilepsy.~* History of convulsive status epilepticus.~* History of primary generalized epilepsy in a first degree relative.~* Known serious medical illness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- all subjects (Type: EXPERIMENTAL): IVIG

Based on this trial design, predict the completion outcome and termination type (if applicable).